Core Viewpoint - Qualigen Therapeutics Inc. will rebrand as AIxCrypto following its stockholder meeting on November 12, 2025, and is launching new initiatives in the Web3 and crypto asset sectors [1] Group 1: Rebranding and New Initiatives - The company will officially change its name to AIxCrypto and introduce its new business initiatives in the crypto space [1] - AIxCrypto plans to launch the public beta of its BesTrade DeAI Agent by the end of November 2025 and release its EAI RWA Utility Token Whitepaper [2] Group 2: Strategic Goals - AIxCrypto aims to expand the C10 Treasury to $50 million in assets under management (AUM), having completed $12 million in crypto asset allocations as of October 17, 2025 [2] - The company intends to accelerate global growth of the BesTrade DeAI Agent, which will serve as a Meta Exchange optimizing transaction pathways and returns [3] - AIxCrypto plans to launch crypto ecosystem tokens on leading exchanges, supported by a potential C10 stablecoin and EAI + Crypto RWA dual-bridge products [4] Group 3: Company Background - Qualigen Therapeutics, Inc. is a biotechnology company based in Carlsbad, California, focusing on innovative oncology and immunology therapies while expanding into crypto asset and Web3 strategies [5]